Identify and analyze resistance mechanisms faster with our world-leading machine learning systems for sequence-based predictions of resistance.
“We are proud to have partnered with Shionogi to develop a sequence-based diagnostic model to predict susceptibility to the antibiotic cefiderocol.”
Dr. Paul A Rhodes, PhD
CEO & Chief Scientific Officer
NGD
From NGD’s October 2024 press release:
“Our agreement with Next Gen Diagnostics will advance our efforts to provide different testing options for cefiderocol, helping us to understand its complex resistance mechanisms.”
— Dr Boudewijn de Jonge, Director, Microbiology Medical Affairs, Shionogi